Lise Jamieson to Cost-Benefit Analysis
This is a "connection" page, showing publications Lise Jamieson has written about Cost-Benefit Analysis.
Connection Strength
1,454
-
Integrated multi-month dispensing for HIV and hypertension in South Africa: A model of epidemiological impact and cost-effectiveness. J Int AIDS Soc. 2025 Feb; 28(2):e26413.
Score: 0,213
-
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022 12; 9(12):e857-e867.
Score: 0,182
-
Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
Score: 0,171
-
The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis. BMJ Glob Health. 2021 07; 6(Suppl 4).
Score: 0,166
-
The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. AIDS. 2020 05 01; 34(6):883-891.
Score: 0,153
-
Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. J Acquir Immune Defic Syndr. 2018 10 01; 79(2):195-205.
Score: 0,137
-
Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017; 12(10):e0186496.
Score: 0,129
-
Ten-year health impact, economic impact and return on investment of the South African molecular diagnostics programme for HIV, tuberculosis and SARS-CoV-2. BMJ Glob Health. 2024 Dec 03; 9(12).
Score: 0,053
-
Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Glob Health. 2023 Feb; 11(2):e244-e255.
Score: 0,046
-
Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022 09; 10(9):e1298-e1306.
Score: 0,045
-
Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022 05; 9(5):e353-e362.
Score: 0,044
-
Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa. Health Policy Plan. 2021 Nov 11; 36(10):1545-1551.
Score: 0,043
-
Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. J Infect Dis. 2021 04 23; 223(8):1345-1355.
Score: 0,041
-
Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? BMC Public Health. 2017 01 31; 17(1):143.
Score: 0,031